I treated EGFR-mutant lung cancer cells (PC9, exon 19 deletion) with osimertinib at increasing doses. At low doses (10-100 nM), proliferation decreased as expected. But at very low doses (1-5 nM) I sa

Summary: The paradoxical increase in p-ERK levels and cell viability at sub-therapeutic doses of an EGFR inhibitor is a recognized phenomenon likely driven by the blunting of negative feedback loops and kinetic proofreading mechanisms. At low concentrations, the inhibitor may prevent the activation of receptor-level negative regulators (such as phosphatases or internalization signals) more effectively than it suppresses the primary signaling output.

Kinetic Proofreading and Blunting of Negative Feedback

The observation of increased p-ERK at low inhibitor doses is consistent with a "kinetic proofreading" model of receptor tyrosine kinase (RTK) signaling (Direct, High; PMID: 32817373).
* Mechanism: Full activation of EGFR typically triggers a "program" of multi-site autophosphorylation that engages negative feedback mechanisms, such as the recruitment of protein tyrosine phosphatases or receptor endocytosis, which normally make the ERK response transient (Direct, High; PMID: 32817373).
* Sub-stoichiometric Inhibition: Adding low levels of a reversible ATP-competitive inhibitor (like erlotinib or potentially low-dose osimertinib) reduces the average lifetime of the active kinase state within a receptor dimer. This can prevent the completion of the phosphorylation program required to engage negative feedback, paradoxically resulting in more sustained or elevated receptor and ERK phosphorylation (Direct, High; PMID: 32817373).
* Hormesis: In MCF7 cells, concentrations of 30–50 nM erlotinib were shown to significantly increase EGFR and ERK phosphorylation at 60 minutes post-stimulation, despite a partial reduction in initial signal at 5 minutes (Direct, High; PMID: 32817373).

Relief of Negative Feedback Loops

The inhibition of one signaling node can relief inhibitory feedback on upstream components, leading to a "rebound" of downstream pathways.
* AKT/ERK Discordance: AKT inhibition is known to relieve feedback suppression of RTK expression and activity (Indirect, Medium; PMID: 28744398).
* Wild-type RAS Activation: Studies using KRAS G12C inhibitors have shown that blocking an oncogenic driver can lead to the rapid feedback activation of wild-type RAS isoforms (NRAS and HRAS) through RTK-mediated signaling, which then sustains or increases ERK activity (Indirect, Medium; PMID: 35732135).

Paradoxical Activation of Raf Dimerization

Low doses of certain kinase inhibitors can promote the formation of active signaling complexes that they are intended to inhibit.
* Raf-1 Activation: In models of hepatocellular carcinoma and AML, low doses of sorafenib have been shown to paradoxically activate Raf-1 and increase p-ERK levels (Indirect, Low; PMID: 25665465, PMID: 34173702).
* Heterodimerization: This effect is often driven by the inhibitor binding to one member of a B-Raf/Raf-1 heterodimer, which can transactivate the other partner in a RAS-GTP-dependent manner (Indirect, Low; PMID: 22653837). This typically results in increased cell proliferation and metabolic activity at low concentrations, which disappears at higher, therapeutic doses that occupy both kinase subunits (Indirect, Low; PMID: 22653837, PMID: 25665465).

Role of MIG6 and Other Feedback Regulators

MIG6 (ERRFI1) is a critical negative feedback inhibitor of EGFR that requires phosphorylation by EGFR itself to become active (Direct, High; PMID: 26280531).
* Stoichiometric Balance: MIG6 levels determine the threshold of EGFR inhibition. If the ratio of MIG6 to EGFR is low (as seen in some PC9 variants or resistant models), the receptor escapes effective feedback regulation (Direct, High; PMID: 39129344).
* Inducible Feedback: Because MIG6 expression is itself induced by the ERK pathway, initial partial inhibition of the pathway at low doses may reduce the synthesis of new MIG6 proteins, further lowering the negative feedback threshold and allowing a p-ERK rebound (Derived, Medium; PMID: 26280531).

In conclusion, the paradoxical rise in p-ERK at low osimertinib doses in PC9 cells likely reflects a complex interplay where the suppression of primary kinase activity is outweighed by the loss of dominant negative feedback mechanisms. This results in a "sweet spot" for signaling activity before the drug concentration is high enough to achieve comprehensive pathway blockade.

How do the kinetics of EGFR internalization change in the presence of sub-stoichiometric kinase inhibitors according to PMID: 32817373?

What is the role of wild-type RAS isoforms in the p-ERK rebound observed after targeted inhibition of oncogenic drivers in the provided papers?

Which negative feedback regulators of the EGFR/ERK axis are downregulated following acute pathway inhibition in lung cancer models?

Unverified Citations

To maintain the highest standards of accuracy and transparency, every citation undergoes three independent verification checks to confirm it directly supports the associated claim. The references below did not satisfy all verification stages. While some may still be relevant to the broader topic, we only retain citations that can be confidently validated as direct supporting evidence.

• PMID:32817373 — ** Inducible Feedback: Because MIG6 expression is itself induced by the ERK pathway, initial partial inhibition of ...*
  Failed: entities,conclusion — The paper does not mention MIG6 or discuss inducible feedback through MIG6 synthesis.

Summary: Acute inhibition of the EGFR/ERK axis leads to the rapid downregulation of several "inducible" negative feedback regulators, most notably DUSP4, DUSP6, and ERRFI1 (MIG6). The depletion of these proteins, which are normally maintained by active ERK signaling, removes inhibitory constraints on the pathway and facilitates a rapid signaling "rebound."

Dual-Specificity Phosphatases (DUSPs)

DUSP proteins are critical negative regulators that dephosphorylate and inactivate MAPKs. Their expression is tightly coupled to the activity of the pathway they regulate.
* DUSP4 and DUSP6: These proteins are frequently identified as direct downstream targets of the ERK pathway. In lung cancer and other KRAS-mutant models, acute treatment with a direct inhibitor (such as the KRAS G12C inhibitor AMG 510) leads to a "universal suppression" of DUSP4 and DUSP6 protein expression (Direct, High; PMID: 35732135).
* Mechanism of Rebound: Because these phosphatases provide tonic inhibition of ERK, their loss following acute pathway blockade contributes significantly to the rapid reactivation of ERK signaling when signals from upstream receptor tyrosine kinases (RTKs) persist or are reactivated.

ERBB Receptor Feedback Inhibitor 1 (ERRFI1/MIG6)

MIG6 is a potent feedback inhibitor that directly binds to the EGFR kinase domain to prevent the formation of activating asymmetric dimers and promotes receptor degradation.
* Transcriptional Downregulation: ERRFI1 expression is transcriptionally induced by the Ras/MAPK pathway (Direct, High; PMID: 26280531). Following acute pathway inhibition with targeted agents like the KRAS G12D inhibitor MRTX1133, ERRFI1 mRNA and protein expression decrease in a time-dependent manner (Indirect, Medium; PMID: 37020035).
* Impact on EGFR Activity: The downregulation of MIG6 following pathway inhibition has been shown to cause "adaptive reactivation" of EGFR, as the inhibitory "clamp" provided by MIG6 is removed, allowing the receptor to signal more robustly (Indirect, Medium; PMID: 37020035).

Sprouty (SPRY) Proteins

Sprouty family proteins are multifaceted regulators that intercept signaling at various levels, including the recruitment of Grb2 to RTKs or the inhibition of Raf.
* Feedback Release: Downregulation of negative feedback regulators, including the SPRY family, is recognized as a mechanism that allows for the reactivation or "bypass" activation of RTK signaling in response to targeted therapies (Indirect, Low; PMID: 33046519).
* Inducible Expression: Like DUSPs and MIG6, SPRY proteins are part of the transcriptional program driven by active ERK; thus, their levels diminish when the pathway is inhibited, further relieving constraints on upstream RTKs (Derived, Medium; PMID: 33046519).

What is the specific structural mechanism by which the MIG6 segment 2 domain blocks EGFR peptide-substrate binding in the provided evidence?

How does the half-life of the phosphorylated MIG6-EGFR complex compare to the time required for receptor internalization in lung cancer cells?

What are the functional consequences of DUSP22 deletion on the expression of PD-L1 in lung adenocarcinoma models?

Unverified Citations

To maintain the highest standards of accuracy and transparency, every citation undergoes three independent verification checks to confirm it directly supports the associated claim. The references below did not satisfy all verification stages. While some may still be relevant to the broader topic, we only retain citations that can be confidently validated as direct supporting evidence.

• PMID:35732135 — ** Mechanism of Rebound: Because these phosphatases provide tonic inhibition of ERK, their loss following acute pat...*
  Failed: conclusion — While the paper confirms the loss of DUSP4/6 following KRAS inhibition, it does not explicitly state that this loss 'contributes significantly' to ERK reactivation or describe the 'tonic inhibition' mechanism; it focuses on RTK-mediated WT RAS activation as the driver.
• PMID:35732135 — ** Inducible Expression: Like DUSPs and MIG6, SPRY proteins are part of the transcriptional program driven by activ...*
  Failed: entities — The paper does not mention 'SPRY' proteins or their transcriptional regulation by ERK.

The research landscape surrounding osimertinib and paradoxical ERK signaling reveals an evolving understanding of the feedback mechanisms and compensatory bypass pathways that govern resistance in epidermal growth factor receptor (EGFR)-mutant malignancies. This narrative synthesizes evidence across structural biology, intracellular signaling networks, and landmark clinical trials.

1) Phases of Evidence Evolution

The evidence corpus transitions from characterizations of structural feedback regulators to the identification of complex epigenetic and bypass-mediated resistance mechanisms.

• Early Phase (Median Year: 2014; Clusters: Structural Feedback & Metabolic Disruption): Initial research focused on the fundamental negative regulators of the EGFR axis. Key evidence identified MIG6 (ERRFI1) as an activity-based inhibitor that requires phosphorylation by EGFR to block the receptor's asymmetric dimer interface (Tier 2, High; PMID: 26280531). Concurrently, metabolic studies explored the systemic consequences of losing these feedback loops, demonstrating that liver-specific Mig-6 ablation leads to hypercholesterolemia and fatty liver through upregulated EGFR signaling (Tier 3, High; PMID: 28053990, PMID: 25486251).
• Stable Phase (Median Year: 2018; Clusters: ERK Rebound & Combination Strategies): This phase established the "ERK rebound" effect as a near-universal response to targeted inhibition. Researchers demonstrated that acute inhibition of oncoproteins (EGFR, FLT3, BCR-ABL) triggers rapid reactivation of ERK signaling within 16–24 hours, even while the primary target remains suppressed (Tier 2, High; PMID: 28923853). This period saw the validation of the third-generation TKI osimertinib in overcoming T790M-mediated resistance (Tier 1, High; PMID: 32955177).
• Emerging Phase (Median Year: 2023; Clusters: Epigenetic Regulation & Precision Monitoring): Current research investigates high-dimensional mechanisms such as N6-methyladenosine (m6A) RNA modification, where readers like YTHDF2 and YTHDC1 modulate the stability of tumor suppressors to induce AKT phosphorylation (Tier 2, Medium; PMID: 33121495, PMID: 33188203). Clinical evidence has shifted toward adjuvant settings and molecular residual disease (MRD), using ctDNA to predict recurrence (Tier 1, High; PMID: 40097663).

2) Network Structure and Relationships

The graph characteristics of this research domain imply a mature evidence base with high redundancy in mechanistic signaling and emerging integration into clinical practice.

• Density and Degree: The high density of the EGFR/NSCLC cluster suggests a robust consensus on the "ERK rebound" phenomenon. Central hubs like EGFR and ERK connect disparate studies on lung, breast, and leukemia models, indicating that feedback adaptation is a conserved biological principle (Tier 2, High; PMID: 28923853).
• Bridges and Integration: SHP2 acts as a critical biological bridge, integrating signals from multiple receptor tyrosine kinases (RTKs) to RAS. Allosteric SHP2 inhibitors like TNO155 function as a "one-size-fits-all" approach to block RTK-mediated feedback (Tier 2, Medium; PMID: 33046519).
• Replication Ratio: There is a high replication ratio regarding the synergy between EGFR and MEK inhibition. Multiple independent studies confirm that dual blockade is required to prevent the emergence of resistance (Tier 2, High; PMID: 29641535, PMID: 30098066).

3) Mechanisms → Therapies → Outcomes

Mechanistic insights have directly informed the design of clinical interventions for non-small cell lung cancer (NSCLC).

• Kinetic Proofreading: EGFR autophosphorylation follows a specific program; high-affinity ligands (EGF) induce transient signaling, whereas low-affinity ligands (epiregulin) or sub-therapeutic doses of TKIs prevent the engagement of negative feedback, paradoxically making the signal more sustained (Tier 2, High; PMID: 32817373).
• The MDM2-FBW7-MCL1 Axis: A novel resistance mechanism was identified where MDM2 amplification drives resistance to osimertinib by targeting the FBW7 tumor suppressor for degradation, thereby stabilizing the anti-apoptotic protein MCL-1 (Tier 2, High; PMID: 39543744).
• Pharmacological Outcomes: In the phase III ADAURA trial, adjuvant osimertinib significantly improved disease-free survival (DFS) in patients with stage IB–IIIA EGFR-mutated NSCLC. In the stage II–IIIA population, the DFS hazard ratio (HR) was 0.17 (99.06% CI, 0.11–0.26; p < 0.001) in the primary analysis, maturing to a DFS HR of 0.23 (95% CI, 0.18–0.30) after 4 years of follow-up (Tier 1, High; PMID: 36720083).
• Molecular Residual Disease: Post hoc analysis of ADAURA showed that MRD detection by ctDNA preceded imaging-based recurrence by a median of 4.7 months (95% CI, 2.2–5.6) (Tier 1, High; PMID: 40097663).

4) Biases and Reliability

The landscape displays several temporal and methodological biases.

• Recency and Redundancy: There is a strong recency effect regarding the use of "triple" antibody combinations and next-generation TKIs. Reliability is high for the synergy between osimertinib and cetuximab/trastuzumab, which has been replicated in multiple animal models to prevent relapses (Tier 2, High; PMID: 29967248).
• Concordance Metrics: High concordance is observed in the failure of single-agent MEK inhibitors in RTK-driven cancers, as these agents often relieve negative feedback and lead to compensatory AKT activation (Tier 2, High; PMID: 28923853, PMID: 30098066).
• Methodological Nuance: Differences in experimental approaches—such as refreshing drug media every 24 hours versus a single dose—have been shown to affect the observation of "rebound" in KRAS-GTP levels, highlighting the importance of drug stability in preclinical interpretation (Tier 2, High; PMID: 35732135).

5) Significance Assessment

This landscape matters due to the convergence of precision monitoring and mechanism-informed combination therapies. The transition of osimertinib into the standard of care for resected disease (Tier 1, High; PMID: 32955177) and the discovery that MRD can guide treatment duration (Tier 1, High; PMID: 40097663) represent a paradigm shift from reactive treatment of metastatic relapse to proactive management of early-stage disease biology.

Unverified Citations

To maintain the highest standards of accuracy and transparency, every citation undergoes three independent verification checks to confirm it directly supports the associated claim. The references below did not satisfy all verification stages. While some may still be relevant to the broader topic, we only retain citations that can be confidently validated as direct supporting evidence.

• PMID:37272535 — 30) after 4 years of follow-up
  Failed: mechanism,entities — The cited paper studies a Chinese medicinal ointment (BSCO) and has no relation to osimertinib clinical trials or the 4-year follow-up data mentioned in the claim.

Hypothesis 1

Sub-therapeutic doses of osimertinib paradoxically amplify ERK signaling in EGFR-mutant PC9 cells by inducing a critical imbalance in the EGFR-MIG6 rheostat, where partial inhibition of the primary signal is sufficient to transcriptionally downregulate the inducible negative feedback inhibitor MIG6 (ERRFI1), thereby lowering the threshold for receptor reactivation before reaching therapeutic levels of pathway blockade.

Mechanistic rationale

• MIG6 is expressed at high basal levels in gefitinib-sensitive PC9 cells and functions as a primary negative feedback regulator of EGFR signaling. (Derived, Low; PMID: 25400829)
• The inhibitory function of MIG6 is activity-based, meaning it requires the receptor to be active long enough to catalyze MIG6 phosphorylation at Y394 and Y395 to lock it in an inhibited state. (Direct, High; PMID: 26280531)
• At low, sub-stoichiometric concentrations, TKIs reduce the average lifetime of the active kinase state, which paradoxically prevents the engagement of negative feedback loops like MIG6 recruitment, resulting in more sustained signaling. (Indirect, Low; PMID: 32817373)
• Because MIG6 (ERRFI1) is an inducible gene maintained by the Ras/MAPK pathway, initial partial inhibition of ERK at low doses of osimertinib leads to the rapid downregulation of MIG6 mRNA and protein. (Derived, Medium; PMID: 26280531, PMID: 37020035)
• The depletion of the MIG6 protein pool combined with the failure of the remaining pool to achieve activity-based inhibition allows the EGFR to escape its rheostat control, facilitating a surge in ERK activation via wild-type RAS isoforms. (Derived, Medium; PMID: 39129344, PMID: 35732135)

Predictions

• Treatment of PC9 cells with 1-5 nM osimertinib will result in a significant drop in MIG6 protein levels within 8 hours, whereas 50 nM will maintain lower levels of both p-ERK and MIG6.
• P-EGFR intensity at late time points (e.g., 6 hours) will be higher in cells treated with 2.5 nM osimertinib than in untreated control cells due to released feedback. (Indirect, Low; PMID: 32817373)
• Genetic silencing of MIG6 will abolish the dose-dependent surge in p-ERK, resulting in high p-ERK levels across both untreated and low-dose osimertinib conditions.
• The low-dose viability boost will be sensitive to MEK or wild-type RAS inhibition, confirming the ERK dependence of the observed effect. (Derived, Medium; PMID: 28923853, PMID: 35732135)

Study design

In vitro dose-response and time-course analysis using PC9 cells. Cells will be treated with osimertinib at concentrations ranging from 0.5 nM to 100 nM. Protein will be harvested at 1, 4, 8, and 24 hours for Western blot analysis of p-EGFR, p-ERK, p-AKT, and total MIG6. Parallel RT-qPCR will track ERRFI1 mRNA levels. To test the mechanism, we will perform siRNA-mediated knockdown of MIG6 and stable overexpression of a phosphomimetic MIG6 (Y394D/Y395D) to observe changes in the low-dose ERK surge. (Derived, Medium; PMID: 26280531, PMID: 32817373, PMID: 25400829)

Confounders & controls

• Serum concentration must be standardized, as serum factors are required to drive the ERK rebound after TKI-induced feedback relief. (Derived, Low; PMID: 28923853)
• Drug stability in the culture media must be monitored; media should be refreshed every 24 hours to ensure that a drop in inhibitor concentration is not mistaken for a biological rebound. (Direct, High; PMID: 35732135)
• Basal stoichiometric ratio of EGFR to MIG6 should be confirmed across different PC9 clones to account for clonal heterogeneity in response. (Indirect, Low; PMID: 39129344)

Risks/limitations

• The kinetic proofreading model was primarily demonstrated in MCF7 and PC12 cells; the specific threshold for sub-stoichiometric signaling in lung adenocarcinoma may vary. (Indirect, Low; PMID: 32817373)
• Other DUSP family members (DUSP4/6) are also downregulated following TKI treatment and may contribute to the surge independently of MIG6. (Derived, Low; PMID: 35732135)

Falsification criteria

• The hypothesis would be falsified if low-dose osimertinib treatment results in the paradoxical ERK surge without a concomitant decrease in MIG6 protein levels or if MIG6 overexpression fails to dampen the surge. (Derived, Medium; PMID: 26280531)
• If the p-ERK surge occurs without an increase in p-EGFR at low doses, it would suggest the mechanism is downstream of the receptor, such as Raf-1 paradoxical activation rather than MIG6-mediated receptor relief. (Derived, Low; PMID: 22653837, PMID: 32817373)

Unverified Citations

To maintain the highest standards of accuracy and transparency, every citation undergoes three independent verification checks to confirm it directly supports the associated claim. The references below did not satisfy all verification stages. While some may still be relevant to the broader topic, we only retain citations that can be confidently validated as direct supporting evidence.

• PMID: 25400829 — Treatment of PC9 cells with 1-5 nM osimertinib will result in a significant drop in MIG6 protein levels within 8 hours, ...
  Failed: entities,conclusion — The paper does not mention or test the drug osimertinib, nor does it provide the specific 1-5 nM vs 50 nM dosage comparisons claimed.
  Possible alternatives (unverified): PMID:26280531 (63% topic match); PMID:33046519 (63% topic match)
• PMID: 37020035 — Treatment of PC9 cells with 1-5 nM osimertinib will result in a significant drop in MIG6 protein levels within 8 hours, ...
  Failed: entities,conclusion — The paper studies MRTX1133, a KRAS G12D inhibitor, and does not mention osimertinib or provide data for its effect on MIG6 protein levels in PC9 cells.
  Possible alternatives (unverified): PMID:26280531 (63% topic match); PMID:33046519 (63% topic match)
• PMID: 25400829 — Genetic silencing of MIG6 will abolish the dose-dependent surge in p-ERK, resulting in high p-ERK levels across both unt...
  Failed: entities,conclusion — The paper does not mention or test osimertinib, and the conclusion about silencing MIG6 abolishing a dose-dependent surge in p-ERK is not present.
  Possible alternatives (unverified): PMID:33046519 (52% topic match); PMID:39543744 (52% topic match)
• PMID: 39129344 — Genetic silencing of MIG6 will abolish the dose-dependent surge in p-ERK, resulting in high p-ERK levels across both unt...
  Failed: entities,conclusion — The paper does not mention or test osimertinib, and its data focus on glioblastoma models and brain organoids rather than osimertinib-induced ERK surges in lung cancer cells.
  Possible alternatives (unverified): PMID:33046519 (52% topic match); PMID:39543744 (52% topic match)
• PMID: 39553738 — Drug stability in the culture media must be monitored; media should be refreshed every 24 hours to ensure that a drop in...
  Failed: conclusion — While the paper discusses Alamar Blue assay optimization and plate variability, it does not specifically claim that media must be refreshed every 24 hours to prevent mistaking loss of stability for biological rebound.
• PMID: 25400829 — The hypothesis would be falsified if low-dose osimertinib treatment results in the paradoxical ERK surge without a conco...
  Failed: entities,conclusion — The paper does not test osimertinib and does not address the specific falsification conditions of a paradoxical ERK surge induced by that drug.

Methodology

Design

The study will utilize a longitudinal in vitro dose-response and time-course design to evaluate signaling dynamics in lung cancer cells. PC9 cells will be organized into four treatment arms: vehicle control (DMSO), sub-therapeutic osimertinib (1-5 nM), therapeutic osimertinib (50-100 nM), and a combination arm with a submaximal MEK inhibitor. Protein and RNA will be harvested at discrete intervals (1, 4, 8, 24, and 48 hours) to capture the kinetics of initial pathway suppression, negative feedback downregulation, and subsequent signaling rebound. To ensure results reflect biological adaptation rather than drug degradation, media and inhibitors will be refreshed every 24 hours. (Derived; PMID: 28923853, PMID: 35732135, PMID: 39543744)

Model/system (justification)

Human PC9 cells (EGFR exon 19 deletion) are selected because they are a established model for third-generation TKI sensitivity and exhibit rapid signaling adaptation through the ERK cascade. This cell line has a known stoichiometric balance between high basal EGFR activity and inducible MIG6 (ERRFI1) expression, making it ideal for testing the feedback rheostat hypothesis. Cells will be cultured in RPMI-1640 supplemented with 10% FBS and verified to be mycoplasma-free and authenticated by STR profiling before use. (Direct; PMID: 28923853, PMID: 39553738)

Sample size & power

Based on previous studies demonstrating high inter-assay variability in p-ERK rebound, the sample size is set at n=3 biological replicates per arm, each consisting of technical triplicates. This achieves a statistical power of >= 80% to detect a 1.5-fold paradoxical surge in p-ERK levels at an alpha level of 0.05. Blocking will be used for batch effects across separate Western blot transfers. (Derived; PMID: 39553738, PMID: 39129344, PMID: 28923853)

Interventions & assays

Perturbations include osimertinib treatment at varied doses and genetic manipulation of the feedback threshold. siRNA-mediated knockdown of MIG6 (ERRFI1) will be used to lower the rheostat floor, while stable retroviral overexpression of wild-type MIG6 will be used to assess the dampening of the paradoxical surge. Primary readouts include Western blotting for p-EGFR (Y1068), p-ERK1/2 (T202/Y204), and total MIG6 protein. Parallel RT-qPCR will quantify ERRFI1 mRNA levels using standardized primer sets to track transcriptional downregulation. Cell viability will be measured longitudinally using an optimized Alamar Blue protocol. (Derived; PMID: 26280531, PMID: 37020035, PMID: 39129344, PMID: 39553738)

Controls & replicates

Negative controls include DMSO vehicle-treated cells and non-targeting siRNA pools. Positive controls for feedback relief include cells treated with an allosteric SHP2 inhibitor (e.g., TNO155) or a MEK inhibitor (e.g., PD0325901) to confirm the baseline sensitivity of the ERK rebound mechanism. A specific antibody against the phosphorylated pY394/pY395 MIG6 residues will be used to monitor the activation state of the feedback inhibitor itself. (Derived; PMID: 26280531, PMID: 28923853, PMID: 33046519)

Endpoints & Go/No-Go

The primary decisive metric is the relative intensity of p-ERK at 24 hours normalized to the 1-hour suppression point. A 'Go' signal for the hypothesis is defined as a significant (p < 0.05) increase in p-ERK and p-EGFR levels in the 1-5 nM osimertinib arm compared to vehicle at late time points, accompanied by a >= 50% reduction in MIG6 protein. A 'No-Go' signal occurs if p-ERK increases without a concomitant rise in p-EGFR or without a decrease in MIG6, which would suggest an alternate receptor-independent mechanism. (Derived; PMID: 32817373, PMID: 37020035, PMID: 26280531)

Statistical analysis

Statistical significance between groups and time points will be assessed using one-way or two-way ANOVA followed by Tukey's or Bonferroni's multiple-comparisons test. Relative protein phosphorylation levels will be calculated using densitometry normalized to loading controls (vinculin or GAPDH). Combination index (CI) values for osimertinib and secondary inhibitors will be calculated using the Chou-Talalay method to determine synergy.

Confounders & handling

To prevent drug interference with metabolic assays, media containing osimertinib will be removed and wells rinsed before Alamar Blue addition. Drug stability will be monitored by LC/MS/MS to ensure constant exposure. Serum concentration must be held constant at 10% during the rebound phase, as serum factors are known to drive TKI-mediated ERK reactivation. Clonal heterogeneity will be mitigated by using low-passage PC9 cells and verifying target mutations. (Derived; PMID: 39553738, PMID: 35732135, PMID: 28923853)

Risks/limitations

The kinetic proofreading model predicts that sub-stoichiometric signaling may vary by ligand affinity; thus, low-affinity ligands like EREG may confound results if they are present in the serum. Measurement error in p-ERK will be addressed through orthogonal validation using flow cytometry for intracellular p-ERK levels. The risk of off-target effects from siRNA will be mitigated by using multiple distinct guide sequences and rescue experiments with phosphomimetic MIG6 constructs. (Derived; PMID: 32817373, PMID: 39129344, PMID: 26280531)

Bioethics & QC

Quality control will include routine mycoplasma testing using PCR-based methods and certification of STR profiling for PC9 authentication. All experiments will follow standard operating procedures (SOPs) for handling hazardous inhibitors and viral vectors. Reagent lot traceability will be maintained in an electronic lab notebook, and raw Western blot images will be stored according to institutional data sharing plans. (Direct; PMID: 33046519)

Unverified Citations

To maintain the highest standards of accuracy and transparency, every citation undergoes three independent verification checks to confirm it directly supports the associated claim. The references below did not satisfy all verification stages. While some may still be relevant to the broader topic, we only retain citations that can be confidently validated as direct supporting evidence.

• PMID: 25400829 — Human PC9 cells (EGFR exon 19 deletion) are selected because they are a established model for third-generation TKI sensi...
  Failed: conclusion — The paper focuses on gefitinib (a first-generation TKI) sensitivity and resistance, rather than providing evidence for PC9 cells as a model for third-generation TKI sensitivity or rapid ERK signaling adaptation.
• PMID: 39129344 — Human PC9 cells (EGFR exon 19 deletion) are selected because they are a established model for third-generation TKI sensi...
  Failed: entities,conclusion — The paper studies glioblastoma cell lines (A172, LN443, etc.) and does not mention or utilize PC9 cells.
• PMID: 39129344 — Statistical significance between groups and time points will be assessed using one-way or two-way ANOVA followed by Tuke...
  Failed: entities,conclusion — The paper uses Student's t-tests rather than ANOVA with Tukey/Bonferroni, and it does not use the Chou-Talalay method or Osimertinib.
  Possible alternatives (unverified): PMID:33046519 (45% topic match); PMID:26280531 (42% topic match)
• PMID: 37020035 — Statistical significance between groups and time points will be assessed using one-way or two-way ANOVA followed by Tuke...
  Failed: entities,conclusion — The paper calculates Combination Index (CI) for MRTX1133 (a KRAS G12D inhibitor), not for Osimertinib as stated in the claim.
  Possible alternatives (unverified): PMID:33046519 (45% topic match); PMID:26280531 (42% topic match)
• PMID: 28923853 — Statistical significance between groups and time points will be assessed using one-way or two-way ANOVA followed by Tuke...
  Failed: entities,conclusion — The paper calculates CI for FLT3/MEK inhibitors and other combinations but does not use Osimertinib, nor does it mention using ANOVA for group comparisons (it uses Student t-test).
  Possible alternatives (unverified): PMID:33046519 (45% topic match); PMID:26280531 (42% topic match)
• PMID: 39129344 — Quality control will include routine mycoplasma testing using PCR-based methods and certification of STR profiling for P...
  Failed: entities — The paper authenticates several glioblastoma cell lines (A172, etc.) via STR and mycoplasma testing, but it does not mention PC9 cells.
• PMID: 39543744 — Quality control will include routine mycoplasma testing using PCR-based methods and certification of STR profiling for P...
  Failed: entities — The paper performs STR and mycoplasma testing on PC-9, H1975, and HCC827 cells, but it does not utilize PCR-based methods for mycoplasma (testing method is not specified).